Jonas Alex Morales Saute

List of Publications by Year
in descending order

72	1,792	218677	302126
papers	citations	26 h-index	39 g-index

73	73	73	2782
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	D<scp>NAJC</scp>6<scp>M</scp>utations <scp>A</scp>ssociated <scp>W</scp>ith <scp>E</scp>arlyâ€<scp>O</scp>nset <scp>P</scp>arkinson's <scp>D</scp>isease. Annals of Neurology, 2016, 79, 244-256.	5.3	148
2	Ataxia Rating Scalesâ€"Psychometric Profiles, Natural History and Their Application in Clinical Trials. Cerebellum, 2012, 11, 488-504.	2.5	101
3	Childhood amyotrophic lateral sclerosis caused by excess sphingolipid synthesis. Nature Medicine, 2021, 27, 1197-1204.	30.7	96
4	Hereditary spastic paraplegia type 5: natural history, biomarkers and a randomized controlled trial. Brain, 2017, 140, 3112-3127.	7.6	87
5	Nonmotor and extracerebellar features in Machadoâ€Joseph disease: A review. Movement Disorders, 2013, 28, 1200-1208.	3.9	79
6	Interleukin-6 Serum Levels in Patients with Parkinsonâ€™s Disease. Neurochemical Research, 2009, 34, 1401-1404.	3.3	75
7	A neurological examination score for the assessment of spinocerebellar ataxia 3 (SCA3). European Journal of Neurology, 2008, 15, 371-376.	3.3	70
8	A randomized, phase 2 clinical trial of lithium carbonate in Machadoâ€Joseph disease. Movement Disorders, 2014, 29, 568-573.	3.9	65
9	Evidence that folic acid deficiency is a major determinant of hyperhomocysteinemia in ParkinsonÂ´s disease. Metabolic Brain Disease, 2009, 24, 257-269.	2.9	61
10	A systematic review and evidence-based guideline for diagnosis and treatment of Menkes disease. Molecular Genetics and Metabolism, 2019, 126, 6-13.	1.1	48
11	Peripheral Oxidative Stress Biomarkers in Spinocerebellar Ataxia Type 3/Machadoâ€"Joseph Disease. Frontiers in Neurology, 2017, 8, 485.	2.4	47
12	Progression Rate of Neurological Deficits in a 10-Year Cohort of SCA3 Patients. Cerebellum, 2010, 9, 419-428.	2.5	45
13	Clinical and molecular characterization of hereditary spastic paraplegias: A next-generation sequencing panel approach. Journal of the Neurological Sciences, 2017, 383, 18-25.	0.6	44
14	Effects of Depressive-Like Behavior of Rats on Brain Glutamate Uptake. Neurochemical Research, 2010, 35, 1164-1171.	3.3	41
15	Machado Joseph disease: clinical and genetic aspects, and current treatment. Expert Opinion on Orphan Drugs, 2015, 3, 517-535.	0.8	41
16	MR Imaging in Spinocerebellar Ataxias: A Systematic Review. American Journal of Neuroradiology, 2016, 37, 1405-1412.	2.4	41
17	Body Mass Index is Inversely Correlated with the Expanded CAG Repeat Length in SCA3/MJD Patients. Cerebellum, 2012, 11, 771-774.	2.5	38
18	Clinicogenetic lessons from 370 patients with autosomal recessive limbâ€girdle muscular dystrophy. Clinical Genetics, 2019, 96, 341-353.	2.0	38

#	Article	IF	Citations
19	Spinocerebellar ataxia type 3/Machadoâ€“Joseph disease: segregation patterns and factors influencing instability of expanded <scp>CAG</scp> transmissions. Clinical Genetics, 2016, 90, 134-140.	2.0	36
20	Serum insulinâ€like system alterations in patients with spinocerebellar ataxia type 3. Movement Disorders, 2011, 26, 731-735.	3.9	35
21	Amnesic effect of GMP depends on its conversion to guanosine. Neurobiology of Learning and Memory, 2006, 85, 206-212.	1.9	32
22	Subcutaneous insulin-like growth factor-1 treatment in spinocerebellar ataxias: An open label clinical trial. Movement Disorders, 2011, 26, 358-359.	3.9	32
23	Neurological manifestations of lysosomal disorders and emerging therapies targeting the CNS. The Lancet Child and Adolescent Health, 2018, 2, 56-68.	5.6	32
24	Occupational therapy in spinocerebellar ataxia type 3: an open-label trial. Brazilian Journal of Medical and Biological Research, 2010, 43, 537-542.	1.5	31
25	Planning future clinical trials in Machado Joseph disease: Lessons from a phase 2 trial. Journal of the Neurological Sciences, 2015, 358, 72-76.	0.6	28
26	Cytokines in Machado Joseph Disease/Spinocerebellar Ataxia 3. Cerebellum, 2016, 15, 518-525.	2.5	27
27	Huntington disease and Huntington diseaseâ€like in a case series from Brazil. Clinical Genetics, 2014, 86, 373-377.	2.0	26
28	Spinocerebellar ataxias in 114 Brazilian families: clinical and molecular findings. Clinical Genetics, 2006, 70, 173-176.	2.0	24
29	Evidence-Based Consensus and Systematic Review on Reducing the Time to Diagnosis of Duchenne Muscular Dystrophy. Journal of Pediatrics, 2019, 204, 305-313.e14.	1.8	24
30	Adenosine deaminase 2 deficiency presenting as spastic paraplegia and systemic vasculitis. Journal of Neurology, 2016, 263, 818-820.	3.6	21
31	Nonâ€motor symptoms in patients with hereditary spastic paraplegia caused by SPG4 mutations. European Journal of Neurology, 2016, 23, 408-411.	3.3	20
32	Depressive Mood is Associated with Ataxic and Non-Ataxic Neurological Dysfunction in SCA3 Patients. Cerebellum, 2010, 9, 603-605.	2.5	17
33	Brazilian consensus on Duchenne muscular dystrophy. Part 1: diagnosis, steroid therapy and perspectives. Arquivos De Neuro-Psiquiatria, 2017, 75, 104-113.	0.8	16
34	Look carefully to the heels! A potentially treatable cause of spastic paraplegia. Journal of Inherited Metabolic Disease, 2015, 38, 363-364.	3.6	15
35	Spinocerebellar ataxia type 3/Machado-Joseph disease starting before adolescence. Neurogenetics, 2016, 17, 107-113.	1.4	15
36	Genetic profile of Brazilian patients with dystrophinopathies. Clinical Genetics, 2017, 92, 199-203.	2.0	13

#	Article	IF	Citations
37	Are Cognitive Changes in Hereditary Spastic Paraplegias Restricted to Complicated Forms?. Frontiers in Neurology, 2019, 10, 508.	2.4	13
38	Diagnostic yield of targeted sequential and massive panel approaches for inherited neuropathies. Clinical Genetics, 2020, 98, 185-190.	2.0	13
39	Spinocerebellar ataxia type 10: common haplotype and disease progression rate in Peru and Brazil. European Journal of Neurology, 2017, 24, 892.	3.3	12
40	Planning Future Clinical Trials for Machado-Joseph Disease. Advances in Experimental Medicine and Biology, 2018, 1049, 321-348.	1.6	12
41	Genetic epidemiology of familial ALS in Brazil. Neurobiology of Aging, 2021, 102, 227.e1-227.e4.	3.1	12
42	Infantile spinocerebellar ataxia type 7: Case report and a review of the literature. Journal of the Neurological Sciences, 2015, 354, 118-121.	0.6	11
43	Neurological outcomes after hematopoietic stem cell transplantation for cerebral X-linked adrenoleukodystrophy, late onset metachromatic leukodystrophy and Hurler syndrome. Arquivos De Neuro-Psiquiatria, 2016, 74, 953-966.	0.8	11
44	<scp>SPG4</scp>â€related hereditary spastic paraplegia: frequency and mutation spectrum in Brazil. Clinical Genetics, 2014, 86, 194-196.	2.0	10
45	Clinical aspects of hereditary spastic paraplegia 76 and novel CAPN1 mutations. Clinical Genetics, 2018, 94, 482-483.	2.0	8
46	Clinical and molecular characterization of a large cohort of childhood onset hereditary spastic paraplegias. Scientific Reports, 2021, 11, 22248.	3.3	8
47	Cancer in Machadoâ€“Joseph disease patientsâ€”low frequency as a cause of death. Cancer Genetics, 2017, 212-213, 19-23.	0.4	6
48	Autosomal recessive spastic ataxia of Charlevoix-Saguenay: a family report from South Brazil. Arquivos De Neuro-Psiquiatria, 2017, 75, 339-344.	0.8	6
49	State biomarkers for Machado Joseph disease: Validation, feasibility and responsiveness to change. Genetics and Molecular Biology, 2019, 42, 238-251.	1.3	6
50	A Prospective Study of SCA3 Gait Ataxia Described through a Markovian Method. Neuroepidemiology, 2010, 34, 163-170.	2.3	5
51	Clinical Scales Predict Significant Videofluoroscopic Dysphagia in Machado Joseph Disease Patients. Movement Disorders Clinical Practice, 2015, 2, 260-266.	1.5	5
52	Dropped head syndrome as a manifestation of Charcotâ€“Marieâ€“Tooth disease type 4C. Neuromuscular Disorders, 2019, 29, 138-141.	0.6	5
53	Progression of Functional Gait in Hereditary Spastic Paraplegias. Cerebellum, 2021, , 1.	2.5	5
54	The role of lithium in ALS remains unknown. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders, 2010, 11, 574-574.	2.1	4

#	Article	IF	Citations
55	Riluzole in patients with hereditary cerebellar ataxia. Lancet Neurology, The, 2016, 15, 788-789.	10.2	4
56	When ataxia is not just ataxia. Nature Clinical Practice Neurology, 2007, 3, E2-E2.	2.5	4
57	Diagnostic yield of multi-gene panel for muscular dystrophies and other hereditary myopathies. Neurological Sciences, 2022, 43, 4473-4481.	1.9	4
58	Effects of 3Âweeks GMP oral administration on glutamatergic parameters in mice neocortex. Purinergic Signalling, 2012, 8, 49-58.	2.2	3
59	Prevalence of oropharyngeal dysphagia in hereditary spastic paraplegias. Arquivos De Neuro-Psiquiatria, 2019, 77, 843-847.	0.8	3
60	Autonomic dysfunction in hereditary spastic paraplegia type 4. European Journal of Neurology, 2019, 26, 687-693.	3.3	2
61	Rapid-Onset Dystonia-Parkinsonism Phenotype Consistency for a Novel Variant of ATP1A3 in Patients Across 3 Global Populations. Neurology: Genetics, 2021, 7, e562.	1.9	2
62	Evoked potentials as biomarkers of hereditary spastic paraplegias: A case-control study. PLoS ONE, 2021, 16, e0259397.	2.5	2
63	Accuracy of muscle fasciculations for the diagnosis of later-onset spinal muscle atrophy. Neuromuscular Disorders, 2022, 32, 763-768.	0.6	2
64	A Cerebral Autosomal Dominant Arteriopathy With Subcortical Infarcts and Leukoencephalopathy Mimics on Brain Magnetic Resonance Imaging in Myotonic Dystrophy Type I. JAMA Neurology, 2017, 74, 866.	9.0	1
65	Letter re: Cathepsin Aâ€“related arteriopathy with strokes and leukoencephalopathy (CARASAL). Neurology, 2017, 88, 1776-1776.	1.1	1
66	Neurological Phenotypes Associated with AAAS-Related Disorders: Spastic Ataxia and Complex Spastic Paraplegia. Cerebellum, 2020, 19, 465-468.	2.5	1
67	Juliano Moreira: the black Brazilian who greatly influenced the modern school of Neurology in Brazil. Arquivos De Neuro-Psiquiatria, 2021, 79, 650-653.	0.8	1
68	Broad clinical and laboratory spectrum found in 9 Niemannâ€“Pick disease type C Southern Brazilian patients. Molecular Genetics and Metabolism, 2015, 114, S35.	1.1	0
69	Challenges in quantifying ataxia in core and comorbid early onset ataxias. Developmental Medicine and Child Neurology, 2017, 59, 350-351.	2.1	0
70	Clinical trials for genetic diseases in Latin America. American Journal of Medical Genetics, Part C: Seminars in Medical Genetics, 2021, 187, 381-387.	1.6	0
71	Speech and swallowing characteristics in patients with facioscapulohumeral muscular dystrophy. Arquivos De Neuro-Psiquiatria, 2022, , .	0.8	0
72	Cognitive profile of patients with facioscapulohumeral muscular dystrophy. Dementia E Neuropsychologia, 2021, 15, 541-547.	0.8	0